Effects of new treatments on chronic lymphocytic leukemia outcomes
Outcomes for CLL patients treated with novel therapy
['FUNDING_R01'] · MAYO CLINIC ROCHESTER · NIH-10912726
This study is looking at how well a combination of Ibrutinib and Rituximab works for people with chronic lymphocytic leukemia (CLL) compared to standard chemotherapy, and it aims to help doctors figure out which patients might do best with these newer treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-10912726 on ClinicalTrials.gov |
What this research studies
This research investigates the outcomes of patients with chronic lymphocytic leukemia (CLL) who are treated with a combination of Ibrutinib and Rituximab, compared to traditional chemotherapy. The study aims to develop predictive models that can identify which patients are likely to benefit from these novel therapies and who may require alternative treatments. By analyzing various prognostic factors, the research seeks to enhance treatment personalization and improve patient outcomes. Patients participating in this research may undergo assessments to determine their response to therapy and the durability of their remission.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic lymphocytic leukemia who are considering or currently receiving treatment with Ibrutinib and Rituximab.
Not a fit: Patients with CLL who are not eligible for Ibrutinib and Rituximab treatment or those with advanced disease requiring immediate intervention may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more tailored treatment strategies for CLL patients, improving their chances of long-term remission and reducing unnecessary exposure to toxic therapies.
How similar studies have performed: Previous research has shown promising results with similar treatment approaches, indicating a potential for significant advancements in CLL therapy.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KAY, NEIL E — MAYO CLINIC ROCHESTER
- Study coordinator: KAY, NEIL E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.